RVL Pharmaceuticals PLC Investor Relations Material
Latest events
Q2 2023
RVL Pharmaceuticals PLC
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from RVL Pharmaceuticals PLC
Access all reports
RVL Pharmaceuticals PLC is a specialty pharmaceutical company that focuses on developing and commercializing products in the ocular and medical aesthetics sectors. Its main product, Upneeq (oxymetazoline hydrochloride ophthalmic solution, 0.1%), is FDA-approved for the treatment of acquired blepharoptosis, or low-lying eyelids, offering a non-surgical option for adults. The company serves underserved patient populations primarily in the United States and operates in several international markets. RVL Pharmaceuticals is headquartered in Bridgewater, New Jersey, and its shares are listed on the OTC Markets.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
RVLP
Country
🇺🇸 United States